









Markets
/
Stocks
/
nasdaq-acb
/

Aurora Cannabis Inc

ACB

5.180USD

+0.190+3.81%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

291.39MMarket Cap

LossP/E TTM



Aurora Cannabis Inc

5.180

+0.190+3.81%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

101 / 175

Overall Ranking

259 / 4723

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

32.000

Target Price

+443.29%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally, and the propagation of vegetables and ornamental plants in North America. Its segments include Canadian Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. It also has a controlling interest in Bevo Farms Ltd., North America's supplier of propagated vegetables and ornamental plants in North America. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, TerraFarma Inc., Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 85.67% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD 1.58M.%!(EXTRA int=2)

Undervalued

The company’s latest PE is -15.21, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 11.00M shares, increasing 13.36% quarter-over-quarter.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 7.63, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 72.04M, representing a year-over-year increase of 18.09%, while its net profit experienced a year-over-year increase of 334.47%.

Score

Industry at a Glance

Previous score

7.59

Change

0.04



Financials

8.64

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

5.85

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.42

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.23

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -15.21, which is -99.16% below the recent high of -0.13 and 58.27% above the recent low of -6.34.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 101/175

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 7.33, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Aurora Cannabis Inc is 32.00, with a high of 32.00 and a low of 32.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

32.000

Target Price

+443.29%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Aurora Cannabis Inc

ACB

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.63, which is lower than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 5.64 and the support level at 4.46, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.57

Change

0.06

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.015

Neutral

RSI(14)

55.714

Neutral

STOCH(KDJ)(9,3,3)

64.941

Buy

ATR(14)

0.210

Low Volatility

CCI(14)

91.053

Neutral

Williams %R

46.925

Neutral

TRIX(12,20)

0.036

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

5.002

Buy

MA10

4.971

Buy

MA20

5.065

Buy

MA50

4.865

Buy

MA100

4.932

Buy

MA200

4.749

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Mirae Asset Global Investments (USA) LLC

2.30M

+769.05%

Tidal Investments LLC

1.42M

+8.69%

Goldman Sachs & Company, Inc.

731.52K

+4.14%

Renaissance Technologies LLC

Star Investors

666.33K

-6.76%

Global X Investments Canada Inc.

345.01K

-0.37%

Morgan Stanley Canada Limited

290.50K

+35.46%

Citadel Advisors LLC

277.90K

+333.33%

Group One Trading, L.P.

88.74K

+114.17%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.95, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 3.23. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.